UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 385

Sortiert nach

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Cancer research (Chicago, Ill.), 2017-10, Vol.77 (19), p.5374-5383

2017

Volltextzugriff (PDF)

Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement

Cancer Immunology, Immunotherapy, 2021-05, Vol.70 (5), p.1465-1474

2021

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Frontiers in immunology, 2023-03, Vol.14, p.1090533-1090533

2023

Volltextzugriff (PDF)

Meeting the New Commission on Cancer Operative Standards: Where Do We Stand Now?

Military medicine, 2023-07, Vol.188 (7-8), p.e1558-e1562

2023

Volltextzugriff (PDF)

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Cancer medicine (Malden, MA), 2019-08, Vol.8 (10), p.4678-4687

2019

Volltextzugriff (PDF)

Clinical Development of the E75 Vaccine in Breast Cancer

Breast care (Basel, Switzerland), 2016-04, Vol.11 (2), p.116-121

2016

Volltextzugriff (PDF)

Overcoming Cancer Immune Tolerance and Escape

Clinical cancer research, 2009-02, Vol.15 (3), p.749-751

2009

Volltextzugriff (PDF)

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Journal of the American College of Surgeons, 2010-02, Vol.210 (2), p.140-147

2010

Volltextzugriff (PDF)

Immunotherapy as a partner for HER2-directed therapies

Expert review of anticancer therapy, 2021-07, Vol.21 (7), p.739-746

2021

Volltextzugriff (PDF)

Prolonged Survival Following Intra-abdominal Mycobacterium abscessus Infection Without Antimicrobial Therapy or Surgical Intervention

The American surgeon, 2023-11, Vol.89 (11), p.4977-4980

2023

Volltextzugriff (PDF)

ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination

Annals of surgical oncology, 2021-10, Vol.28 (11), p.6138-6139

2021

Volltextzugriff (PDF)

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer, 2012-05, Vol.118 (10), p.2594-2602

2012

Volltextzugriff (PDF)

The development and use of the E75 (HER2 369-377) peptide vaccine

Future oncology (London, England), 2016-06, Vol.12 (11), p.1321-1329

2016

Volltextzugriff (PDF)

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention

Clinical immunology (Orlando, Fla.), 2022-12, Vol.245, p.109095, Article 109095

2022

Volltextzugriff (PDF)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Annals of surgical oncology, 2021-10, Vol.28 (11), p.6126-6137

2021

Volltextzugriff (PDF)

Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival

Annals of surgical oncology, 2022-09, Vol.29 (9), p.6015-6028

2022

Volltextzugriff (PDF)

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

Oncotarget, 2021-11, Vol.12 (23), p.2318-2319

2021

Volltextzugriff (PDF)

The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy

Journal of surgical oncology, 2024-07, Vol.130 (1), p.109-116

2024

Volltextzugriff (PDF)

Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 Pandemic

The Journal of surgical research, 2022-07, Vol.275, p.43-47

2022

Volltextzugriff (PDF)

Critical issues in cancer vaccine trial design

Vaccine, 2015-12, Vol.33 (51), p.7386-7392

2015

Volltextzugriff (PDF)

Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters

Journal of surgical oncology, 2024-02, Vol.129 (2), p.244-253

2024

Volltextzugriff (PDF)

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Vaccine, 2018-05, Vol.36 (23), p.3247-3253

2018

Volltextzugriff (PDF)

Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ

Cancer prevention research (Philadelphia, Pa.), 2023-06, Vol.16 (6), p.333-341

2023

Volltextzugriff (PDF)

Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ

Cancer prevention research (Philadelphia, Pa.), 2023-06, Vol.16 (6), p.333-341

2023

Volltextzugriff (PDF)

1 – 25 von 385

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(321)
Mit Volltextzugriff
(321)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(384)
Japanisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Meeting the New Commission on Cancer Operative Standards: Where Do We Stand Now?

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Clinical Development of the E75 Vaccine in Breast Cancer

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

Overcoming Cancer Immune Tolerance and Escape

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Immunotherapy as a partner for HER2-directed therapies

Prolonged Survival Following Intra-abdominal Mycobacterium abscessus Infection Without Antimicrobial Therapy or Surgical Intervention

ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

The development and use of the E75 (HER2 369-377) peptide vaccine

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy

Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 Pandemic

Critical issues in cancer vaccine trial design

Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ

Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ

Suchergebnisse filtern